CORONA CORONA Remedies Q1 FY27 results (Apr–Jun 2026) and concall
CORONA Remedies Limited reported a strong Q1 FY27, with revenue growing 21.9% year-on-year to INR422 crores, significantly exceeding its 15% guidance. The India business led this growth, expanding 22.7% and outperforming the Indian Pharmaceutical Market. Profitability also saw robust improvement, with EBITDA growing 33.5% and PAT increasing 30.1%, driven by favorable product mix and operating leverage. The company also successfully commercialized its new Europe-GMP approved hormone manufacturing facility and integrated the Wokadine acquisition.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 21.6%, net profit up 30.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 314 | 298 | 294 | 347 | 361 +15% | 342 +15% | 353 +20% | 422 +22% |
| EBITDA | 67 | 69 | 54 | 70 | 78 +16% | 83 +20% | 62 +15% | 93 +33% |
| Net profit | 43 | 45 | 31 | 46 | 52 +21% | 41 −9% | 45 +45% | 60 +30% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
